...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Nuclear Medicine >Advancing Targeted Radionuclide Therapy Through the National Cancer Institute’s Small Business Innovation Research Pathway
【24h】

Advancing Targeted Radionuclide Therapy Through the National Cancer Institute’s Small Business Innovation Research Pathway

机译：通过美国国家癌症研究所的小型企业创新研究途径推进靶向放射性核素治疗

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs of the National Cancer Institute (NCI) are congressionally mandated set-aside programs that provide research funding to for-profit small businesses for the development of innovative technologies and treatments that serve the public good. These two programs have an annual budget of $159 million (in 2017) and serve as the NCI’s main engine of innovation for developing and commercializing cancer technologies. In collaboration with the NCI’s Radiation Research Program, the NCI SBIR Development Center published in 2015–2017 three separate requests for proposals from small businesses for the development of systemic targeted radionuclide therapy (TRT) technologies to treat cancer. TRT combines a cytotoxic radioactive isotope with a molecularly targeted agent to produce an anticancer therapy capable of treating local or systemic disease. This article summarizes the NCI SBIR funding solicitations for the development of TRTs and the research proposals funded through them.
机译：美国国立癌症研究所（NCI）的小型企业创新研究（SBIR）和小型企业技术转让（STTR）计划是国会授权的预留计划，旨在为营利性小型企业提供研究资金，以开发创新技术和治疗方法为公众利益服务。这两个计划的年度预算为1.59亿美元（2017年），是NCI开发和商业化癌症技术的主要创新引擎。 NCI SBIR开发中心与NCI的辐射研究计划合作，于2015-2017年发布了三份小型企业的独立申请书，其中涉及开发用于治疗癌症的全身靶向放射性核素治疗（TRT）技术。 TRT将细胞毒性放射性同位素与分子靶向药物相结合，以产生能够治疗局部或全身性疾病的抗癌疗法。本文总结了NCI SBIR为TRT的开发提供的资助建议以及通过TIR资助的研究建议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号